Chad A. Grotegut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chad A. Grotegut has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
R. Phillips Heine
9 shared publicationsAndra H. James
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina
7 shared publicationsAmy P. Murtha
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
5 shared publications- Amy P. Murtha
Duke University Medical Center, Durham, NC
5 shared publications Liping Feng
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
4 shared publicationsGeeta K. Swamy
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University, Durham, NC
3 shared publications
Latest Publications
- Open Access
- 1 July 2024
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 14 (04) , e274
Corrigendum: The Collection and Application of Autologous Amniotic Fluid to Cesarean Delivery Closure
The authors have brought to the publisher’s attention about the error in one of the column labels in Figure 4 of the above article published on November 18, 2024, in Volume 14, Number 4 in the American Journal of Perinatology Reports (DOI: 10.1055/a-2445-7954). The corrected Figure appear as below. Article published online: 17 December 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 July 2024
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 14 (04) , e274
Open AccessCorrigendum: The Collection and Application of Autologous Amniotic Fluid to Cesarean Delivery Closure
The authors have brought to the publisher’s attention about the error in one of the column labels in Figure 4 of the above article published on November 18, 2024, in Volume 14, Number 4 in the American Journal of Perinatology Reports (DOI: 10.1055/a-2445-7954). The corrected Figure appear as below. Article published online: 17 December 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- Open Access
- 1 July 2024
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 14 (04) , e262-e269
The Collection and Application of Autologous Amniotic Fluid to Cesarean Delivery Closure
Background Amniotic fluid and amnion membranes have been used in surgery specialties to improve wound healing and decrease surgical adhesion formation. Objective The objective was to determine if amniotic fluid could be collected at cesarean delivery and then reapplied to the layers of the closure using the CeaLogic Specimen Collection and Ratio Applicator Kit. Study Design Twenty pregnant individuals who met inclusion and exclusion criteria were enrolled. Amniotic fluid was collected at artificial rupture of the membranes using the collection kit. Autologous amniotic fluid was then transferred to the applicator kit, mixed with calcium chloride solution, and applied directly to each of the surgical repair layers during closure: closed hysterotomy incision, closed fascial incision, closed subcutaneous layer (if applicable), and closed skin. Subjects were then followed for six weeks. Photographs of the incision were taken immediately following surgery, one-week following surgery, and at the four-week postpartum visit. The Modified Hollander Cosmesis Score was used to assess wound appearance. Results Twenty pregnant individuals who met inclusion and exclusion criteria were enrolled and all completed the study. The mean volume of amniotic fluid collected was 30 ± 19 mL. The median (IQR) Modified Hollander Cosmesis Score (Range 0-best, to 6-worst) at the one week and four-week postpartum visits was 0 (0,1) and 0 (0,2), respectively. There were no wound complications nor surgical site infections among the cohort. Further, there were no unscheduled visits for wound issues among any of the subjects. Conclusion The CeaLogic Specimen Collection and Ratio Applicator Kits can be used to collect and reapply autologous amniotic fluid at the time of cesarean delivery. Future studies are needed to determine if the application of autologous amniotic fluid to cesarean delivery closure can improve cosmesis and wound healing, as well as decrease the risk for the development of intraabdominal adhesions.
- 1 July 2024
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 14 (04) , e262-e269
Open AccessThe Collection and Application of Autologous Amniotic Fluid to Cesarean Delivery Closure
Background Amniotic fluid and amnion membranes have been used in surgery specialties to improve wound healing and decrease surgical adhesion formation. Objective The objective was to determine if amniotic fluid could be collected at cesarean delivery and then reapplied to the layers of the closure using the CeaLogic Specimen Collection and Ratio Applicator Kit. Study Design Twenty pregnant individuals who met inclusion and exclusion criteria were enrolled. Amniotic fluid was collected at artificial rupture of the membranes using the collection kit. Autologous amniotic fluid was then transferred to the applicator kit, mixed with calcium chloride solution, and applied directly to each of the surgical repair layers during closure: closed hysterotomy incision, closed fascial incision, closed subcutaneous layer (if applicable), and closed skin. Subjects were then followed for six weeks. Photographs of the incision were taken immediately following surgery, one-week following surgery, and at the four-week postpartum visit. The Modified Hollander Cosmesis Score was used to assess wound appearance. Results Twenty pregnant individuals who met inclusion and exclusion criteria were enrolled and all completed the study. The mean volume of amniotic fluid collected was 30 ± 19 mL. The median (IQR) Modified Hollander Cosmesis Score (Range 0-best, to 6-worst) at the one week and four-week postpartum visits was 0 (0,1) and 0 (0,2), respectively. There were no wound complications nor surgical site infections among the cohort. Further, there were no unscheduled visits for wound issues among any of the subjects. Conclusion The CeaLogic Specimen Collection and Ratio Applicator Kits can be used to collect and reapply autologous amniotic fluid at the time of cesarean delivery. Future studies are needed to determine if the application of autologous amniotic fluid to cesarean delivery closure can improve cosmesis and wound healing, as well as decrease the risk for the development of intraabdominal adhesions.
- Open Access
- 1 July 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (7) , 1515-1524
Performance of a Multianalyte ‘Rule-Out’ Assay in Pregnant Individuals With Suspected Preeclampsia
Background: The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia. Methods: Prospective, multicenter cohort study of pregnant individuals presenting between 28 0/7 and 36 6/7 weeks’ with preeclampsia-associated signs and symptoms. Individuals not diagnosed with preeclampsia after baseline evaluation were enrolled in the study cohort, with those who later developed preeclampsia, classified as cases and compared with a negative control group who did not develop preeclampsia. Individuals with assay values at time of enrollment ≥0.0325, determined using a previously developed algorithm, considered at risk. The primary analysis was the time to develop preeclampsia assessed using a multivariate Cox regression model. Results: One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of preeclampsia of 30.3% (27.6%–33.2%). The time to develop preeclampsia was shorter for those with an at-risk compared with negative assay result (log-rank P P <0.0001]). The performance metrics for the assay to rule-out preeclampsia within 7 days of enrollment showed a sensitivity 76.4% (67.5%–83.5%), negative predictive value 95.0% (92.8%–96.6%), and negative likelihood ratio 0.46 (0.32–0.65). Assay performance improved if delivery occurred <37 weeks and for individuals enrolled between 28 and 35 weeks. Conclusions: We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out preeclampsia within 7 days of enrollment. Registration: The study was registered on Clinicaltrials.gov (Identifier NCT02780414).
- 1 July 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (7) , 1515-1524
Open AccessPerformance of a Multianalyte ‘Rule-Out’ Assay in Pregnant Individuals With Suspected Preeclampsia
Background: The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia. Methods: Prospective, multicenter cohort study of pregnant individuals presenting between 28 0/7 and 36 6/7 weeks’ with preeclampsia-associated signs and symptoms. Individuals not diagnosed with preeclampsia after baseline evaluation were enrolled in the study cohort, with those who later developed preeclampsia, classified as cases and compared with a negative control group who did not develop preeclampsia. Individuals with assay values at time of enrollment ≥0.0325, determined using a previously developed algorithm, considered at risk. The primary analysis was the time to develop preeclampsia assessed using a multivariate Cox regression model. Results: One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of preeclampsia of 30.3% (27.6%–33.2%). The time to develop preeclampsia was shorter for those with an at-risk compared with negative assay result (log-rank P P <0.0001]). The performance metrics for the assay to rule-out preeclampsia within 7 days of enrollment showed a sensitivity 76.4% (67.5%–83.5%), negative predictive value 95.0% (92.8%–96.6%), and negative likelihood ratio 0.46 (0.32–0.65). Assay performance improved if delivery occurred <37 weeks and for individuals enrolled between 28 and 35 weeks. Conclusions: We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out preeclampsia within 7 days of enrollment. Registration: The study was registered on Clinicaltrials.gov (Identifier NCT02780414).
- Open Access
- 1 August 2021
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 37, 100833
Placental uterine artery embolization followed by delayed hysterectomy for placenta percreta: A case series
- 1 August 2021
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 37, 100833
Open AccessPlacental uterine artery embolization followed by delayed hysterectomy for placenta percreta: A case series
- Open Access
- 7 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0243585
Prediction of neonatal morbidity and very preterm delivery using maternal steroid biomarkers in early gestation
Preterm delivery is a common pregnancy complication that can result in significant neonatal morbidity and mortality. Limited tools exist to predict preterm birth, and none to predict neonatal morbidity, from early in pregnancy. The objective of this study was to determine if the progesterone metabolites 11-deoxycorticosterone (DOC) and 16-alpha hydroxyprogesterone (16α-OHP), when combined with patient demographic and obstetric history known during the pregnancy, are predictive of preterm delivery-associated neonatal morbidity, neonatal length of stay, and risk for spontaneous preterm delivery prior to 32 weeks’ gestation. We conducted a cohort study of pregnant women with plasma samples collected as part of Building Blocks of Pregnancy Biobank at the Indiana University School of Medicine. The progesterone metabolites, DOC and 16α-OHP, were quantified by mass spectroscopy from the plasma of 58 pregnant women collected in the late first trimester/early second trimester. Steroid levels were combined with patient demographic and obstetric history data in multivariable logistic regression models. The primary outcome was composite neonatal morbidity as measured by the Hassan scale. Secondary outcomes included neonatal length of stay and spontaneous preterm delivery prior to 32 weeks’ gestation. The final neonatal morbidity model, which incorporated antenatal corticosteroid exposure and fetal sex, was able to predict high morbidity (Hassan score ≥ 2) with an area under the ROC curve (AUROC) of 0.975 (95% CI 0.932, 1.00), while the model without corticosteroid and fetal sex predictors demonstrated an AUROC of 0.927 (95% CI 0.824, 1.00). The Hassan score was highly correlated with neonatal length of stay (p<0.001), allowing the neonatal morbidity model to also predict increased neonatal length of stay (53 [IQR 22, 76] days vs. 4.5 [2, 31] days, above and below the model cut point, respectively; p = 0.0017). Spontaneous preterm delivery prior to 32 weeks’ gestation was also predicted with an AUROC of 0.94 (95% CI 0.869, 1.00). Plasma levels of DOC and 16α-OHP in early gestation can be combined with patient demographic and clinical data to predict significant neonatal morbidity, neonatal length of stay, and risk for very preterm delivery, though validation studies are needed to verify these findings. Early identification of pregnancies at risk for preterm delivery and neonatal morbidity allows for timely implementation of multidisciplinary care to improve perinatal outcomes.
- 7 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0243585
Open AccessPrediction of neonatal morbidity and very preterm delivery using maternal steroid biomarkers in early gestation
Preterm delivery is a common pregnancy complication that can result in significant neonatal morbidity and mortality. Limited tools exist to predict preterm birth, and none to predict neonatal morbidity, from early in pregnancy. The objective of this study was to determine if the progesterone metabolites 11-deoxycorticosterone (DOC) and 16-alpha hydroxyprogesterone (16α-OHP), when combined with patient demographic and obstetric history known during the pregnancy, are predictive of preterm delivery-associated neonatal morbidity, neonatal length of stay, and risk for spontaneous preterm delivery prior to 32 weeks’ gestation. We conducted a cohort study of pregnant women with plasma samples collected as part of Building Blocks of Pregnancy Biobank at the Indiana University School of Medicine. The progesterone metabolites, DOC and 16α-OHP, were quantified by mass spectroscopy from the plasma of 58 pregnant women collected in the late first trimester/early second trimester. Steroid levels were combined with patient demographic and obstetric history data in multivariable logistic regression models. The primary outcome was composite neonatal morbidity as measured by the Hassan scale. Secondary outcomes included neonatal length of stay and spontaneous preterm delivery prior to 32 weeks’ gestation. The final neonatal morbidity model, which incorporated antenatal corticosteroid exposure and fetal sex, was able to predict high morbidity (Hassan score ≥ 2) with an area under the ROC curve (AUROC) of 0.975 (95% CI 0.932, 1.00), while the model without corticosteroid and fetal sex predictors demonstrated an AUROC of 0.927 (95% CI 0.824, 1.00). The Hassan score was highly correlated with neonatal length of stay (p<0.001), allowing the neonatal morbidity model to also predict increased neonatal length of stay (53 [IQR 22, 76] days vs. 4.5 [2, 31] days, above and below the model cut point, respectively; p = 0.0017). Spontaneous preterm delivery prior to 32 weeks’ gestation was also predicted with an AUROC of 0.94 (95% CI 0.869, 1.00). Plasma levels of DOC and 16α-OHP in early gestation can be combined with patient demographic and clinical data to predict significant neonatal morbidity, neonatal length of stay, and risk for very preterm delivery, though validation studies are needed to verify these findings. Early identification of pregnancies at risk for preterm delivery and neonatal morbidity allows for timely implementation of multidisciplinary care to improve perinatal outcomes.
- Open Access
- 4 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (49) , eabc8696
Transcriptome and regulatory maps of decidua-derived stromal cells inform gene discovery in preterm birth
Functional annotations of a placental cell genome aid in identifying genes associated with preterm birth.
- 4 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (49) , eabc8696
Open AccessTranscriptome and regulatory maps of decidua-derived stromal cells inform gene discovery in preterm birth
Functional annotations of a placental cell genome aid in identifying genes associated with preterm birth.
- 15 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (22) , 12435-12443
The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility
Significance: We recently demonstrated that the effects of the β 2 AR agonist clenbuterol to enhance skeletal muscle strength and hypertrophy are mediated via β-arrestin1-dependent signaling. The present study reports the unique ability of carvedilol, previously identified as a β-arrestin-biased agonist at the β 2 AR, to enhance skeletal muscle contractility. This observation was unique among βAR antagonists tested as metoprolol and nadolol failed to stimulate skeletal muscle contractility. Our findings provide insight into the mechanism of carvedilol’s effect on skeletal muscle contractility and demonstrate the unconventional potential utility of a commonly used pharmacologic agent for a previously unappreciated clinical use. We hypothesize that the observed β-arrestin-dependent signaling pathway could be targeted in various clinical conditions associated with decreased functional exercise capacity.
- 15 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (22) , 12435-12443
The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility
Significance: We recently demonstrated that the effects of the β 2 AR agonist clenbuterol to enhance skeletal muscle strength and hypertrophy are mediated via β-arrestin1-dependent signaling. The present study reports the unique ability of carvedilol, previously identified as a β-arrestin-biased agonist at the β 2 AR, to enhance skeletal muscle contractility. This observation was unique among βAR antagonists tested as metoprolol and nadolol failed to stimulate skeletal muscle contractility. Our findings provide insight into the mechanism of carvedilol’s effect on skeletal muscle contractility and demonstrate the unconventional potential utility of a commonly used pharmacologic agent for a previously unappreciated clinical use. We hypothesize that the observed β-arrestin-dependent signaling pathway could be targeted in various clinical conditions associated with decreased functional exercise capacity.
- Open Access
- 27 December 2018
- Published by Springer Nature in Skeletal Muscle
- Vol. 8 (1) , 1-13
β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility
β2-adrenergic receptors (β2ARs) are the target of catecholamines and play fundamental roles in cardiovascular, pulmonary, and skeletal muscle physiology. An important action of β2AR stimulation on skeletal muscle is anabolic growth, which has led to the use of agonists such as clenbuterol by athletes to enhance muscle performance. While previous work has demonstrated that β2ARs can engage distinct signaling and functional cascades mediated by either G proteins or the multifunctional adaptor protein, β-arrestin, the precise role of β-arrestin in skeletal muscle physiology is not known. Here, we tested the hypothesis that agonist activation of the β2AR by clenbuterol would engage β-arrestin as a key transducer of anabolic skeletal muscle growth. The contractile force of isolated extensor digitorum longus muscle (EDL) and calcium signaling in isolated flexor digitorum brevis (FDB) fibers were examined from the wild-type (WT) and β-arrestin 1 knockout mice (βarr1KO) followed by chronic administration of clenbuterol (1 mg/kg/d). Hypertrophic responses including fiber composition and fiber size were examined by immunohistochemical imaging. We performed a targeted phosphoproteomic analysis on clenbuterol stimulated primary cultured myoblasts from WT and βarr1KO mice. Statistical significance was determined by using a two-way analysis with Sidak’s or Tukey’s multiple comparison test and the Student’s t test. Chronic administration of clenbuterol to WT mice enhanced the contractile force of EDL muscle and calcium signaling in isolated FDB fibers. In contrast, when administered to βarr1KO mice, the effect of clenbuterol on contractile force and calcium influx was blunted. While clenbuterol-induced hypertrophic responses were observed in WT mice, this response was abrogated in mice lacking β-arrestin 1. In primary cultured myoblasts, clenbuterol-stimulated phosphorylation of multiple pro-hypertrophy proteins required the presence of β-arrestin 1. We have identified a previously unappreciated role for β-arrestin 1 in mediating β2AR-stimulated skeletal muscle growth and strength. We propose these findings could have important implications in the design of future pharmacologic agents aimed at reversing pathological conditions associated with skeletal muscle wasting.
- 27 December 2018
- Published by Springer Nature in Skeletal Muscle
- Vol. 8 (1) , 1-13
Open Accessβ-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility
β2-adrenergic receptors (β2ARs) are the target of catecholamines and play fundamental roles in cardiovascular, pulmonary, and skeletal muscle physiology. An important action of β2AR stimulation on skeletal muscle is anabolic growth, which has led to the use of agonists such as clenbuterol by athletes to enhance muscle performance. While previous work has demonstrated that β2ARs can engage distinct signaling and functional cascades mediated by either G proteins or the multifunctional adaptor protein, β-arrestin, the precise role of β-arrestin in skeletal muscle physiology is not known. Here, we tested the hypothesis that agonist activation of the β2AR by clenbuterol would engage β-arrestin as a key transducer of anabolic skeletal muscle growth. The contractile force of isolated extensor digitorum longus muscle (EDL) and calcium signaling in isolated flexor digitorum brevis (FDB) fibers were examined from the wild-type (WT) and β-arrestin 1 knockout mice (βarr1KO) followed by chronic administration of clenbuterol (1 mg/kg/d). Hypertrophic responses including fiber composition and fiber size were examined by immunohistochemical imaging. We performed a targeted phosphoproteomic analysis on clenbuterol stimulated primary cultured myoblasts from WT and βarr1KO mice. Statistical significance was determined by using a two-way analysis with Sidak’s or Tukey’s multiple comparison test and the Student’s t test. Chronic administration of clenbuterol to WT mice enhanced the contractile force of EDL muscle and calcium signaling in isolated FDB fibers. In contrast, when administered to βarr1KO mice, the effect of clenbuterol on contractile force and calcium influx was blunted. While clenbuterol-induced hypertrophic responses were observed in WT mice, this response was abrogated in mice lacking β-arrestin 1. In primary cultured myoblasts, clenbuterol-stimulated phosphorylation of multiple pro-hypertrophy proteins required the presence of β-arrestin 1. We have identified a previously unappreciated role for β-arrestin 1 in mediating β2AR-stimulated skeletal muscle growth and strength. We propose these findings could have important implications in the design of future pharmacologic agents aimed at reversing pathological conditions associated with skeletal muscle wasting.
- 1 September 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 217 (3) , 367.e1-367.e9
The association of single-nucleotide polymorphisms in the oxytocin receptor and G protein–coupled receptor kinase 6 (GRK6) genes with oxytocin dosing requirements and labor outcomes
- 1 September 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 217 (3) , 367.e1-367.e9
The association of single-nucleotide polymorphisms in the oxytocin receptor and G protein–coupled receptor kinase 6 (GRK6) genes with oxytocin dosing requirements and labor outcomes